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Zidovudine (AZT) is a reverse transcriptase (RT) inhibitor widely used to treat persons infected with HIV-1 and HIV-2. Recent data on
treated patients suggest differences in the antiviral activity of AZT between HIV-1 and HIV-2. We evaluated the antiviral activity of AZT on
HIV-2 by using multiple approaches including in vitro selection experiments, analysis of growth kinetics with AZT, and phenotypic testing.
A total of 5 wild-type (WT) HIV-2 viruses were used in the analysis. For comparison, 4 control WT HIV-1 strains and one HIV-1 mutant
carrying the 215S mutation were evaluated in parallel. All 5 HIV-1 isolates acquired AZT resistance mutations after 3–6 passages with AZT
or a 4- to 32-fold increase in AZT concentration. Among these viruses, the fastest selection of resistance was seen in HIV-1S215, which
acquired S215Y (1-nucleotide change only) at passage 3 after only 17 days in culture. In contrast, none of the 5 HIV-2 viruses that naturally
have S215 acquired S215Y/F or any other RT mutation during 10 passages with AZT (1025-fold increase in AZT concentration). In the
presence of AZT + didanosine (ddI), 3 of the 5 HIV-1 isolates acquired AZT or ddI resistance mutations, while only ddI resistance mutations
were seen in HIV-2 (4 of 5 isolates). All HIV-2 viruses replicated efficiently in high AZT concentrations and were about 200-fold less
sensitive to AZT than HIV-1. In contrast, HIV-2 and HIV-1 were equally susceptible to ddI, a finding consistent with the selection of HIV-2
mutants with AZT + ddI. Our results demonstrate that the activity of AZT on HIV-2 is lower than previously thought, and emphasize the need
for novel antiretroviral drugs specific for HIV-2.
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Human immunodeficiency virus type 2 (HIV-2) was first
identified in 1985 in Senegal and is endemic in most West
African countries (reviewed in Reeves and Doms, 2002). A
large number of HIV-2 infections are also found in other
geographical regions such as Western Europe and Asia
(Reeves and Doms, 2002). HIV-2 infection differs clinically
from HIV-1 infection by having a longer clinical latency,
lower perinatal and sexual transmission rates, and less
marked immunological abnormalities in asymptomatic indi-
viduals (Reeves and Doms, 2002). Like HIV-1, HIV-2 causes0042-6822/$ - see front matter. Published by Elsevier Inc.
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benefit from treatment with antiretroviral drugs including
reverse transcriptase (RT) and protease inhibitors. However,
information on how HIV-2-infected persons should be best
treated is limited because of the absence of randomized
clinical trials and because most infections occur in develop-
ing countries where few patients are treated. Drug selection
for HIV-2 treatment has been generally guided by in vitro
studies on the activity of available anti-HIV-1 drugs. Such
studies have found comparable susceptibility to nucleoside
RT inhibitors (NRTIs) and protease inhibitors among HIV-1
and HIV-2 with the possible exception of amprenavir, and
documented natural resistance of HIV-2 to non-nucleoside
RT inhibitors (NNRTIs) (Cox et al., 1994; Larder et al., 1990;
Tantillo et al., 1994; Witvrouw et al., 1999, 2004).
AZT was the first antiretroviral drug approved for the
treatment of HIV-1-infected persons and has been found to05) 251 – 264
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2001b; Qari et al., 2001). Although data from HIV-2-
infected patients treated with AZT and other NRTIs are
limited to small cohorts of patients, several observations
suggest differences in the antiviral activity of AZT between
HIV-2 and HIV-1 (Adje-Toure et al., 2003; Brandin et al.,
2003; Descamps et al., 2004; Rodes et al., 2000; van der
Ende et al., 2000, 2003). The genotypic analysis of HIV-2
RT sequences from AZT-treated patients has shown a
remarkably low frequency of selection of AZT mutations
such as K70R or 215Y/F, which in HIV-1 are commonly
associated with high levels of AZT resistance (Adje-Toure et
al., 2003; Brandin et al., 2003; Descamps et al., 2004; Rodes
et al., 2000; van der Ende et al., 2000, 2003). For instance,
Rodes et al. (2000) found absence of 215Y/F in 11 HIV-2-
infected patients that were treated for 7–68 months with
AZT alone or in combination with other NRTIs, and only
one patient acquired the K70R mutation. Similar findings
were recently reported by Adje-Toure et al. (2003), who
found 215Y in only one of 18 patients treated with AZT-
containing regimens, and by van der Ende et al. (2003), who
found absence of 215Y/F or K70R in 6 patients who failed
AZT or d4T-containing regimens. In all these studies,
Q151M was the primary mutation associated with the use
of AZT and other NRTIs (Adje-Toure et al., 2003; Brandin
et al., 2003; Descamps et al., 2004; Rodes et al., 2000; van
der Ende et al., 2000, 2003), as opposed to HIV-1 in which
215Y/F represents the preferential pathway for NRTI
resistance (Brun-Vezinet et al., 1997; Shafer et al., 1994,
1995). The striking differences in the frequency of AZT
mutations and in mutational pathways of resistance between
HIV-1 and HIV-2 have not been seen for other NRTIs such
as lamivudine (3TC), which selects for the M184V mutation
in both HIV-1 and HIV-2 (Adje-Toure et al., 2003; Brandin
et al., 2003; Descamps et al., 2004; Rodes et al., 2000; van
der Ende et al., 2000, 2003).
The low frequency of selection of 215Y/F seen in HIV-2-
infected persons treated with AZT and other NRTIs is
surprising sinceWTHIV-2 RTsequences have Ser at position
215 (TCT), which differs from the mutant 215Y/F (TAT and
TTT, respectively) by a single nucleotide change as opposed
to the 2 nucleotide changes required for theWT T215 of HIV-
1. Therefore, it was expected that selection of 215Y/F would
be favored in HIV-2 since HIV-1 mutants that differ from
215Y/F by a single nucleotide rapidly acquire 215Y with
AZT both in vitro and in vivo (de Ronde et al., 2000; Garcı´a-
Lerma et al., 2001a; Violin et al., 2004). These findings
suggest that the S215Yor Fmutations might confer a minimal
selective advantage for HIV-2 because of a reduced fitness or
because they confer minimal resistance to AZT. Alterna-
tively, it is possible that differences in AZT selective
pressures might be responsible for the low frequency of
selection of AZT mutations in HIV-2. Therefore, additional
analysis of the activity of AZT on HIV-2 is necessary to fully
understand the differences in patterns and frequency of AZT
mutations seen between HIV-1 and HIV-2-infected persons.In the present study, we have re-evaluated the antiviral
activity of AZT on HIV-2 by using multiple approaches
including in vitro selection experiments, analysis of growth
kinetics in the presence of AZT, and drug susceptibility
testing. We demonstrate that the susceptibility of HIV-2 to
AZT is lower than previously thought.Results
Absence of selection of AZT-resistant HIV-2 during
sequential passages with AZT
We first investigated patterns of mutations (amino acids
32–224) in HIV-2 isolates (CDC313019, CDC77618,
GB122HU, CBL20/H9, and ROD) during sequential
passages with increasing concentrations of AZT. For
comparison, the kinetics of selection of resistance mutations
were also evaluated in 5 control HIV-1 isolates including 4
wild type (WT) strains (HXB2, IIIB/H9, CC/H9, and LAI)
and one site-directed mutant carrying the T215S mutation
(HXB2S215).
In the presence of AZT, all 5 HIV-1 strains acquired AZT
resistance mutations after 3–6 passages or an increase in the
concentration of AZT of 4- to 32-fold (from 0.024 to 0.096
or 0.77 Ag/ml, respectively) (Table 1). Among these viruses,
the fastest selection of resistance was seen in HXB2S215,
which acquired the S215Y mutation at passage 3 after only
17 days in culture. Of the remaining 4 HIV-1 strains, HXB2
acquired K70R at passage 5 (day 36) followed by D67N at
passage 8 (day 77), IIIB/H9 acquired K70R at passage 6
(day 41) followed by a mixture of T215S, I, and F at
passage 7 (day 48), CC/H9 acquired D67N at passage 5 (41
days) followed by K70R at passage 6 (day 51), and LAI
acquired D67N at passage 6 (day 38) followed by K70R at
passage 7 (day 50). In contrast to HIV-1, none of the 5 HIV-2
viruses acquired resistance mutations during 10 passages or
an increase in the concentration of AZT of 1025-fold (from
0.024 to 24.6 Ag/ml). Isolates GB122HU and CDC77618
acquired a 104K and a 64K mutation, respectively. However,
104K and 64K were also seen at baseline in CBL-20/H9,
CDC77618, CDC310319, or ROD (see below), indicating
that they represent natural polymorphisms.
To investigate if other mutations might have been
selected outside amino acids 32–224, we expanded our
sequence analysis of HIV-2 RT to amino acid 550 in isolates
collected at passage 8 and 10 with AZT. RT sequences were
then compared to the sequences obtained in baseline
isolates. The results showed a mixture of 298L/P and a
change from 387K/R to 387R in isolate CBL-20/H9 at
passages 8 and 10, and a mixture of 466K/R in isolate
CDC77618 at passages 8 and 10. Isolates GB122HU,
CDC310319, and ROD showed absence of any RT mutation
at these high AZT concentrations (not shown). Overall,
these findings indicate little or no selective pressure by AZT
during this range of drug concentrations. Concentrations of
Table 1
RT mutations in HIV-1 and HIV-2 during passages with AZT
Passage AZT
(Ag/ml)
Time
(days)
Cumulative
time (days)
RT
mutations
HIV-2
CDC310319 1 0.024 4 4 n.d.
2 0.048 4 8 n.d.
3 0.096 5 13 –
4 0.19 4 17 n.d.
5 0.38 4 21 n.d.
6 0.77 4 25 n.d.
7 1.54 4 29 n.d.
8 6.14 5 34 –
9 12.3 6 40 n.d.
10 24.6 5 45 –
CDC77618 1 0.024 4 4 n.d.
2 0.048 3 7 n.d.
3 0.096 5 12 n.d.
4 0.19 6 18 n.d.
5 0.38 6 24 n.d.
6 0.77 5 29 n.d.
7 1.54 4 33 n.d.
8 6.14 5 38 –
9 12.3 6 44 –
10 24.6 5 49 R64R/Ka
CBL-20/H9 1 0.024 4 4 n.d.
2 0.048 3 7 n.d.
3 0.096 4 11 n.d.
4 0.19 4 15 –
5 0.38 6 21 n.d.
6 0.77 5 26 n.d.
7 1.54 4 30 n.d.
8 6.14 5 35 –
9 12.3 6 41 n.d.
10 24.6 5 46 –
GB122 HU 1 0.024 4 4 n.d.
2 0.048 4 8 n.d.
3 0.096 4 12 –
4 0.19 4 16 R104R/K
5 0.38 4 20 R104R/K
6 0.77 4 24 R104R/K
7 1.54 4 28 R104R/K
8 6.14 4 32 R104R/K
9 12.3 5 37 n.d.
10 24.6 5 42 R104R/K
ROD 1 0.024 4 4 n.d.
2 0.048 4 8 n.d.
3 0.096 4 12 –
4 0.19 4 16 –
5 0.38 6 22 n.d.
6 0.77 5 27 n.d.
7 1.54 4 31 n.d.
8 6.14 5 36 –
9 12.3 5 41 n.d.
10 24.6 5 46 –
HIV-1
HXB2S215 1 0.024 7 7 n.d.
2 0.048 4 11 –
3 0.096 6 17 S215Y
4 0.19 6 23 S215Y
5 0.38 6 29 n.d.
6 0.77 6 35 S215Y,
H221H/Y
7 1.54 6 41 n.d.
8 6.14 11 52 S215F/Y,
H221H/Y
Passage AZT
(Ag/ml)
Time
(days)
Cumulative
time (days)
RT
mutations
HXB2 1 0.024 7 7 n.d.
2 0.048 5 12 n.d.
3 0.096 6 18 n.d.
4 0.19 8 26 –
5 0.38 10 36 K70K/R
6 0.77 8 44 K70R
7 1.54 12 60 n.d.
8 6.14 17 77 D67N,
K70R
IIIB-H9 1 0.024 4 4 n.d.
2 0.048 5 9 n.d.
3 0.096 6 15 n.d.
4 0.19 8 23 –
5 0.38 9 32 –
6 0.77 8 41 K70R
7 1.54 7 48 K70R,
T215S/I/F
8 6.14 10 58 L214F,
T215F,
K70K/R
CC/H9 1 0.024 4 4 n.d.
2 0.048 8 12 n.d.
3 0.096 6 18 n.d.
4 0.19 8 26 –
5 0.38 15 41 D67D/N
6 0.77 10 51 D67N/D,
K70R/K
7 1.54 9 60 D67N,
K70R
8 6.14 10 70 D67N,
K70R
LAI 1 0.024 4 4 n.d.
2 0.048 5 9 n.d.
3 0.096 6 15 n.d.
4 0.19 6 21 –
5 0.38 7 28 –
6 0.77 10 38 D67D/N
7 1.54 12 50 D67N,
K70R/K
8 6.14 10 60 D67N,
K70R
– , no mutations observed; n.d., not done.
a Mixed genotype. The first amino acid represents the predominant
genotype observed in the mixture.
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in the culture and could not be evaluated (not shown).
Selection of HIV-2 mutants by sequential passages with AZT
and ddI
We next compared RT mutations selected in HIV-1 and
HIV-2 during culture with both AZT and ddI. Table 2 shows
that 3 of the 5 HIV-1 strains acquired AZT or ddI resistance
mutations such as S215F, D67N, and K65R after 4 to 6
passages with AZT+ddI. Similarly, 4 of the 5 HIV-2 viruses
acquired mutations that are known to be associated with ddI
resistance in HIV-1. Of these viruses, CDC77618 and ROD
acquired the K65R mutation and CBL-20/H9 and
Table 2
RT mutations in HIV-1 and HIV-2 during passages with AZT and ddI
Passage AZT/ddI
(Ag/ml)
Time
(days)
Cumulative
time (days)
RT
mutations
HIV-2
CDC310319 1 0.003/2 7 7 –
2 0.006/4 7 14 –
3 0.012/8 6 20 –
4 0.024/16 8 28 –
5 0.048/32 9 37 –
6 0.096/64 16 53 n.d.
7 0.19/128 12 65 –
8 0.38/256 22 87 –
CDC77618 1 0.003/2 6 6 –
2 0.006/4 7 13 –
3 0.012/8 9 22 –
4 0.024/16 8 30 –
5 0.048/32 9 39 –
6 0.096/64 17 56 K65K/Ra
7 0.19/128 14 70 K65R
8 0.38/256 22 92 K65R,
I189I/M
CBL-20/H9 1 0.003/2 7 7 –
2 0.006/4 6 13 –
3 0.012/8 7 20 –
4 0.024/16 8 28 –
5 0.048/32 9 37 –
6 0.096/64 15 52 n.d.
7 0.19/128 12 64 M184I
GB122 HU 1 0.003/2 7 7 –
2 0.006/4 5 12 –
3 0.012/8 7 19 –
4 0.024/16 8 27 –
5 0.048/32 7 34 –
6 0.096/64 17 51 M184I
7 0.19/128 12 63 M184I,
R104K/R
8 0.38/256 22 85 M184I,
R104K
ROD 1 0.003/2 5 5 –
2 0.006/4 5 10 –
3 0.012/8 7 17 –
4 0.024/16 8 25 –
5 0.048/32 9 34 –
6 0.096/64 17 51 –
7 0.19/128 14 65 –
8 0.38/256 22 87 K64R,
K65R
HIV-1
HXB2S215 1 0.003/2 8 8 –
2 0.006/4 12 20 –
3 0.012/8 20 40 n.d.
4 0.024/16 31 71 H221Y
4b 0.024/16 32 103 H221Y,
S215F
HXB2 1 0.003/2 7 7 –
2 0.006/4 12 19 –
3 0.012/8 15 34 n.d.
4 0.024/16 29 63 E138K
4b 0.024/16 39 102 n.d.
4c 0.024/16 20 122 E138K
5 0.048/32 33 155 E138K
B-H9 1 0.003/2 6 6 –
2 0.006/4 8 14 –
3 0.012/8 11 25 –
4 0.024/16 21 46 K65R
Passage AZT/ddI
(Ag/ml)
Time
(days)
Cumulative
time (days)
RT
mutations
HIV-1
B-H9 4b 0.024/16 14 60 K65R
5 0.048/32 17 77 K65R
CC/H9 1 0.003/2 6 6 –
2 0.006/4 7 13 –
3 0.012/8 19 32 n.d.
4 0.024/16 29 61 –
4b 0.024/16 39 100 –
4c 0.024/16 16 116 –
5 0.048/32 52 168 –
LAI 1 0.003/2 6 6 –
2 0.006/4 7 13 –
3 0.012/8 11 24 n.d.
4 0.024/16 21 45 –
4b 0.024/16 22 67 –
4c 0.024/16 12 79 D67D/N,
H221Y
5 0.048/32 17 96 D67N,
H221Y
– , no mutations observed; n.d., not done.
a Mixed genotype. The first amino acid represents the predominan
genotype observed in the mixture.
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selection of HIV-2 mutants with AZT alone suggests that
ddI may be driving the selection of K65R and M184I in
HIV-2 during culture with AZT and ddI.
Selective pressure by AZT and AZT + ddI in HIV-1 and
HIV-2
The analysis of the relationship between the time required
to observe full cytopathic effect (CPE) in culture and the
increase in the concentration of drug during the passages
may provide an indication of the selective pressure conferred
by the drug/s. Fig. 1 illustrates such a relationship in both
HIV-1 and HIV-2 passaged with AZT or AZT + ddI. In
experiments done with WT HIV-1 and AZT, the time
required to observe full CPE in the passages increased
exponentially with the increase in AZT concentrations
during passages, likely reflecting the selective pressure
conferred by AZT and, possibly, an impairment of fitness
associated with the selection of AZT resistance mutations.
Similar exponential relationship was seen in both HIV-1 and
HIV-2 during passages in the presence of AZT + ddI,
supporting a drug selective pressure by AZT+ddI in these
viruses. In contrast, the time required to observe full CPE in
cultures done with WT HIV-2 and AZT was short and
constant during all the passages (4.6 T 0.07 days). Such a
linear relationship was indicative of a minimal drug selective
pressure in the wide range of AZT concentrations tested, a
finding that is consistent with the absence of selection of
AZT mutations. Fig. 1 also shows that the fluctuations in the
levels of p24 or p27 antigen seen during the entire selection
experiments were similar in HIV-1 and HIV-2, indicating
Fig. 1. Cumulative time in culture and levels of p24 or p27 antigen during passages with AZT or AZT + ddI in HIV-1 and HIV-2. The relationship between the
passages with AZT or AZT + ddI, the cumulative time in culture, and the level of p24 or p27 antigen observed at the end of each passage are shown. Data
reflect the mean cumulative time or p24/p27 antigen levels seen in all the HIV-1 or HIV-2 isolates (bars denote the standard error of the mean (SEM)). Arrows
indicate the median passage at which an AZT or a ddI resistance mutation was seen.
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associated with differences in virus production.
HIV-2 can replicate efficiently in the presence of a high
concentration of AZT
We next investigated the ability of HIV-2 to replicate in
MT-4 cells in the presence of a high concentration of AZT.
We selected a concentration of AZT of 12.3 Ag/ml, which is
2800-fold higher than the median EC50 value of AZT for
HIV-1. Replication capacities were measured in baseline
HIV-2 isolates, in HIV-2 isolates collected after 8 passages
with AZT (Table 1, p8 isolates), and in baseline HIV-2
isolates that were adapted to grow in MT-4 cells by limited
passages (5 passages) in the absence of drug. The replication
kinetics of baseline HIV-1 and of HIV-1 isolates collected at
passage 6 with AZT (Table 1, p6 isolates) were also
evaluated in parallel cultures done with 1.6 Ag/ml of AZT.
Fig. 2 shows the kinetics of p27 or p24 antigen production
seen in all these cultures.
All the 5 HIV-2 p8 isolates replicated efficiently in the
presence of 12.3 Ag/ml of AZT and showed detectable p27
antigen after 4 days of culture (Fig. 2A). Similarly, all the 5
baseline HIV-2 isolates replicated efficiently with AZT (Fig.
2B). However, the kinetics of p27 antigen production seen
in these isolates were delayed compared to those of p8isolates. For instance, isolates CDC310319, CDC77618,
CBL-20/H9, and GB122HU showed little or no p27 antigen
production during the first 10 days of culture followed by a
rapid increase in p27 from day 10 to day 14. Fig. 2C shows
that such a delay in virus production was minimal when the
baseline isolates were previously adapted to grow in MT-4
cells, indicating that the observed differences in virus
replication likely reflect a reduced ability of baseline isolates
to replicate in MT-4 cells. A comparison of RT sequences
between baseline HIV-2 isolates and isolates collected after
12–14 days of culture with AZT showed absence of RT
mutations, indicating that the efficient replication seen with
AZT was not due to the selection of AZT-resistant mutants
(data not shown).
Fig. 2D shows the kinetics of HIV-1 replication in MT-4
cells in the presence of AZT. Three of the four baseline
HIV-1 viruses tested (HXB2S215, HXB2, and CC/H9) did
not replicate with AZT, and only IIIB/H9 had evidence of
low levels of viral replication at day 14. In contrast, the
AZT-resistant HIV-1 isolates HXB2S215Y and IIIB/H9K70R
that were selected at passage 6 with AZT were able to
replicate efficiently in the presence of AZT, a finding
confirming the reduced susceptibility of these mutants to
AZT (Fig. 2D).
The ability of HIV-2 to replicate in high AZT concen-
trations was also evaluated in PBMCs and CEM174 cells
Fig. 2. Replication kinetics of HIV-2 and HIV-1 in the presence of 12.2 Ag/ml or 1.6 Ag/ml of AZT, respectively. (A) HIV-2 isolates collected after 8 passages
with AZT (p8 isolates). (B) Baseline HIV-2 isolates. (C) Baseline HIV-2 isolates adapted to grow in MT-4 cells by limited passages in the absence of drug. (D)
Baseline HIV-1 isolates (HXB2S215, HXB2, IIIB/H9, and CC/H9) and HIV-1 isolates collected after 6 passages with AZT (HXB2S215Y and IIIB/H9K70R; p6
isolates). Replication kinetics were evaluated in at least two independent experiments. A representative experiment is shown. A broken line denotes the limit of
detection of the p24 and p27 assay.
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isolates replicated efficiently in both PBMCs and CEM174
cells (data not shown). In the presence of 2 Ag/ml of AZT,
all the 5 HIV-2 isolates replicated efficiently while little or
no virus replication was seen in the 4 control WT HIV-1
isolates (Fig. 3). These findings indicate that the efficient
replication of HIV-2 with AZT is not restricted to MT-4
cells, and confirm that HIV-2 is resistant to AZT.
Susceptibility of HIV-2 to AZT and ddI and comparison with
HIV-1
We next compared the susceptibility to AZT and ddI
among HIV-1 and HIV-2. We calculated EC50 and EC90
values for AZT and ddI using the MT-4/MTT assay in a
regular and an extended format. In the regular format of the
assay, EC50 and EC90 values were calculated after 5 days of
culture. In the extended format, EC50 and EC90 values were
calculated after 10 or 14 days of culture. Tables 3 and 4 show
the EC50 and EC90 values for AZTand ddI seen at days 5, 10,
and 14 in 4 baseline HIV-2 (CDC77618, CBL-20/H9, ROD,
and GB122HU) and 4 baseline HIV-1 viruses (HXB2,
HXB2S215, CC/H9, and IIIB/H9).
At day 5, the median EC50 value for AZT in HIV-2 was
0.010 Ag/ml (range = 0.004–0.038) and was only 2.2-foldhigher than the median EC50 value seen in HIV-1 (0.0043
Ag/ml, range = 0.0029–0.0058). However, at day 10, the
median EC50 value for AZT in HIV-2 (6.3 Ag/ml; range =
0.29 to >25) was >140-fold higher than the median EC50
value seen in HIV-1 (0.045 Ag/ml; range = 0.018–0.084).
Table 3 shows that while EC50 values in HIV-1 only
increased 10-fold from day 5 to day 10, such increase was
>630-fold in HIV-2. At day 14, EC50 values for AZT
further increased in HIV-2 (median = 25 Ag/ml; range =
11.9 to >25), while only a 2.8-fold change was seen in HIV-
1 from day 10 to day 14.
Similar findings were seen when the EC90 values were
compared (Table 3). However, these values were already
higher in HIV-2 than in HIV-1 at day 5. Table 3 shows that
the median EC90 value for AZT seen in HIV-2 at day 5 (0.47
Ag/ml; range = 0.02–1.82) was 22.7-fold higher than the
median EC90 value seen in HIV-1 (0.021 Ag/ml; range =
0.007–0.029).
The differences in AZT susceptibility between HIV-1 and
HIV-2 were not due to an insufficient viral replication and
lower cytotoxicity of HIV-2 compared to HIV-1. Fig. 4
shows the loss of MTT signal (OD at 540 nm) due to HIV-1
and HIV-2 replication seen in the absence of AZT and in the
presence of a high AZT concentration (5 Ag/ml). In the
absence of AZT, both HIV-1 and HIV-2 showed maximal
Fig. 3. Replication capacity of baseline HIV-1 and HIV-2 isolates in CEM174 and PBMCs in the presence of 2 Ag/ml AZT. (A) Replication of HIV-2 in CEM174.
(B) Replication of HIV-1 in CEM174. (C) Replication of HIV-2 in PBMCs. (B) Replication of HIV-1 in PBMCs. Replication capacities were evaluated in two
independent experiments. Mean p24 values from a representative experiment performed in duplicate (CEM174) or quadruplicate (PBMCs) are shown. A broken
line indicates the limit of detection of the p24 and p27 assay.
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OD values seen in the MTT assay. In contrast, viral
cytotoxicity at high AZT concentrations was low in both
HIV-1 and HIV-2 at day 5, and increased overtime only in
HIV-2, illustrating the lower protective effect of AZT onTable 3
Comparison of the EC50 and EC90 values for AZT between HIV-1 and
HIV-2
EC50 (Ag/ml) EC90 (Ag/ml)
Day
5
Day
10
Day
14
Day
5
Day
10
Day
14
HIV-1
HXB2 0.0035 0.018 0.019 0.023 0.03 0.03
HXB2S215 0.0029 0.019 0.082 0.007 0.31 0.18
IIIB/H9 0.0050 0.084 0.375 0.029 0.17 0.82
CC/H9 0.0058 0.071 0.165 0.018 0.21 0.70
Median 0.0043 0.045 0.124 0.021 0.19 0.44
HIV-2
ROD 0.038 >25a >25 1.82 >25 >25
CBL-20/H9 0.008 11.9 >25 0.68 >25 >25
CDC77618 0.011 0.72 11.9 0.25 3.28 >25
GB122HU 0.004 0.29 >25 0.02 0.78 >25
Median 0.010 6.3 25 0.47 >14 >25
Ratio HIV-2/HIV-1 2.2 >140 >202 22.7 >74 >57
a EC50 values > 25 Ag/ml were given an arbitrary value of 25 for the
calculation of medians.HIV-2 compared to HIV-1 (Fig. 4). Taken together, these
findings demonstrate a lower antiviral activity of AZT on
HIV-2, which may explain the absence of mutations during
passages with AZT and the efficient replication seen at high
AZT concentrations.
We also compared the susceptibility to ddI among HIV-1
and HIV-2 (Table 4). In contrast to AZT, the EC50 values forTable 4
Comparison of the EC50 and EC90 values for ddI between HIV-1 and HIV-2
EC50 (Ag/ml) EC90 (Ag/ml)
Day
5
Day
10
Day
14
Day
5
Day
10
Day
14
HIV-1
HXB2 0.55 3.57 3.34 2.7 6.8 7.2
HXB2S215 1.87 4.21 17.6 7.4 18 38
IIIB/H9 2.25 12 15.4 7.3 31 36
CC/H9 0.47 6.69 17.6 5.6 28 37
Median 1.21 5.45 16.5 6.45 23 36
HIV-2
ROD 3.66 17.7 34.2 7.7 34 141
CBL-20/H9 3.29 17.7 16.7 6.7 34 34
CDC77618 3.28 9.3 15.8 7.4 30 33
GB122HU 0.72 5.1 18.2 2.4 26 38
Median 3.29 13.5 17.5 7.1 32 36
Ratio HIV-2/HIV-1 2.7 2.5 1.1 1.1 1.4 1
Fig. 4. Cytotoxicity of HIV-1 and HIV-2 isolates by the standard (day 5) and the modified (days 10 and 14) MT4/MTT phenotypic assay. Data show the mean
cytotoxicity (OD at 540 nm) observed in the absence and in the presence of AZT (5 Ag/ml) in 4 HIV-1 (HXB2, HXB2S215, CC/H9, and IIIB/H9) and 4 HIV-2
(CDC77618, CBL20/H9, GB122HU, and ROD) isolates. Bars denote the standard error of the mean (SEM).
P. Reid et al. / Virology 336 (2005) 251–264258ddI were similar in HIV-1 and HIV-2 at days 5, 10, and 14.
At day 5, the median EC50 value in HIV-2 was 3.29 Ag/ml
(range = 0.72–3.66) and was only 2.7-fold higher than the
median value calculated in HIV-1 (1.21 Ag/ml; range =
0.47–2.25). At days 10 and 14, these values were 2.5- and
1.1-fold higher in HIV-2 than in HIV-1, respectively. Similar
findings were seen when the EC90 values were compared,
further supporting that both viruses are equally susceptibleFig. 5. Inhibition curves for AZT and ddI seen in HIV-1 and HIV-2. Curves were
concentrations after 5 days of virus replication (standard MT-4/MTT assay) or af
reflect the mean values observed in 4 HIV-1 (HXB2, HXB2S215, CC/H9, and IIIBto ddI. Fig. 5 illustrates the inhibition curves for AZT and
ddI observed in all these viruses at days 5, 10, and 14.
Enzymatic susceptibility of HIV-2 RT to AZT-TP
To investigate if the observed AZT resistance of HIV-2
could be due to an increased ability of HIV-2 RT to
discriminate against AZT-TP, we compared the EC50 valuesobtained by measuring the percentage of cell protection at increasing AZT
ter 10 and 14 days of virus replication (extended MT-4/MTT assay). Data
/H9) and 4 HIV-2 (CDC77618, CBL20/H9, GB122HU, and ROD) isolates.
Fig. 6. Enzymatic susceptibility for AZT-TP of HIV-1 and HIV-2. Data
show the mean RT inhibition values observed in three HIV-2 isolates
(CDC310319, CBL-20/H9, and ROD) and three HIV-1 isolates (HXB2,
MN/H9, and LAI) tested in duplicate in two separate experiments. The
susceptibility for AZT-TP of a control AZT-resistant HIV-1 mutant carrying
the Q151M mutation (L2S.4) is also shown.
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enzymatic RT assay. An AZT-resistant HIV-1 mutant
carrying Q151M (LS2.4) was also evaluated as a control
for efficient discrimination (Garcı´a-Lerma et al., 2000). Fig.
6 compares the susceptibility for AZT-TP seen in three HIV-
2 and three HIV-1 isolates. As expected, the control HIV-
1Q151M mutant displayed a reduced susceptibility to AZT-TP
(4.7-fold) in this assay compared to WT HIV-1. However,
the mean IC50 for AZT-TP seen in HIV-2 (0.0023 AM) was
similar to the mean IC50 value seen in WT HIV-1 (0.0036
AM), indicating that HIV-1 and HIV-2 have similar abilities
to discriminate against AZT-TP.Fig. 7. Comparison of RT sequences between baseline HIV-1 and HIV-2 isolates.
were seen in WT HIV-2 isolates are shown in bold.Comparison of baseline RT sequences among HIV-2 and
HIV-1
We next compared the RT sequences (amino acids 37–
224) of all the baseline HIV-2 viruses with those of HIV-1.
The overall amino acid sequence homology between HIV-1
and HIV-2 RT was 64% (range = 63–65%). Fig. 7 shows
that none of the HIV-2 viruses had primary mutations
associated with phenotypic resistance to AZT in HIV-1 such
as K70R, S215Y/F, or Q151M. However, all the HIV-2
isolates had amino acid changes at positions associated with
NRTI resistance in HIV-1 such as codons 69 (T69N), 75
(V75I), 118 (V118I), 210 (L210N), 215 (T215S), and 219
(K219E). Fig. 7 also shows that the 64K and 104K
mutations that were observed in HIV-2 isolates GB122HU
and CDC77618 during passages with AZT were present at
baseline in 3 of the 5 HIV-2 isolates, indicating that 64K and
104K represent natural polymorphisms.Discussion
This study represents the first comprehensive analysis of
the antiviral activity of AZT on HIV-2. We evaluated the
activity of AZT in both primary isolates and laboratory-
adapted strains by measuring growth kinetics in the
presence of AZT and by assessing the evolution of
resistance in selection experiments with AZT. We found
that all 5 HIV-2 viruses tested were able to replicate
efficiently with a concentration of AZT that was about
3000-fold higher than the EC50 value for HIV-1. We alsoThe amino acids that are associated with AZT resistance in HIV-1 and that
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passages with AZT, indicating little or no selective pressure
by AZT on these viruses. While some of the isolates showed
mixtures at positions 64, 104, 298, 387, and 466, these
mutations were frequently seen at baseline in other HIV-2
isolates. However, the impact of these polymorphic residues
on the observed AZT resistance of HIV-2 is not known.
Taken together, these findings are consistent with a limited
antiviral activity of AZT on HIV-2. The opposite was seen
with HIV-1, and AZT-resistant HIV-1 mutants were easily
selected under the same in vitro conditions and showed
patterns of mutations that were consistent with those
previously seen (Gao et al., 1992; Larder et al., 1991).
Interestingly, despite the need of only 1-nt change to evolve
from the WT S215 to 215Y/F, none of the HIV-2 isolates
acquired 215Y/F after 10 passages with AZT, while an HIV-
1 mutant having S215 acquired 215Y after only 3 passages
with AZT. The lack of selection of S215Y/F in HIV-2
strongly supports a low selective advantage of 215Y/F with
AZT and is consistent with the low frequency of S215Y/F
seen in treated patients (Adje-Toure et al., 2003; Brandin et
al., 2003; Descamps et al., 2004; Rodes et al., 2000; van der
Ende et al., 2000, 2003).
The selection of K65R and M184I in HIV-2 during
passages with AZT and ddI was suggestive of an antiviral
activity of ddI on HIV-2. The patterns of mutations seen in
vitro were in agreement with clinical data showing K65R
and M184I in some HIV-2-infected patients who fail
treatment with ddI (Adje-Toure et al., 2003; Brandin et
al., 2003; Descamps et al., 2004; van der Ende et al., 2000).
The efficient antiviral activity of ddI on HIV-2 was further
confirmed by our phenotypic analysis that showed that HIV-
2 and HIV-1 were equally susceptible to ddI.
Consistent with previous studies, we found that testing
for drug susceptibility by the MT4/MTT assay under
conditions used for HIV-1 showed that HIV-2 and HIV-1
were equally sensitive to AZT (Cox et al., 1994; Larder et
al., 1990; Witvrouw et al., 2004). However, our demon-
stration that the conditions of the phenotypic assay are
critical to assess the susceptibility of HIV-2 for AZT is
significant. We show that high levels of AZT resistance in
HIV-2 were only detected when the phenotypic assay was
extended from day 5 to days 10–14. We demonstrate that
such a dependency on assay conditions was limited to AZT
and HIV-2, and that both HIV-1 and HIV-2 had similar EC50
values for ddI in the two assay formats. The differences in
AZT susceptibility between HIV-1 and HIV-2 by the
standard and the modified MT4/MTT assay were not due
to an insufficient HIV-2 replication in the absence of drug,
since both HIV-1 and HIV-2 showed maximal cytotoxicity
at day 5. However, at high AZT concentrations, HIV-1
replication was inhibited while HIV-2 was able to replicate
efficiently. The finding that the peak of HIV-2 replication at
high AZT concentrations was only seen after 7–14 days of
culture is in agreement with the need to extend the MT4/
MTT assay to detect AZT resistance. The factors underlyingsuch a delay in replication are not known but may be related
to the ability of the HIV-2 isolates to replicate in MT4 cells,
or to different susceptibilities of HIV-1 and HIV-2 to
changes in dTTP/AZT-TP ratios that might arise during
culture of MT4 cells. Additional studies are needed to
evaluate these and other possibilities. Our findings empha-
size the importance of testing for drug susceptibility by the
modified assay for other drugs, particularly for d4T, and
highlight the need of studies of selection of resistant mutants
to confirm the activity of anti-HIV-1 drugs on HIV-2.
While our in vitro data on the reduced susceptibility of
HIV-2 to AZT suggest little drug pressure by AZT in vivo,
HIV-2 mutants carrying Q151M and less frequently K70R/
S, S215T/Y/F, or E219D have been noted in a few patients
treated with AZT or AZT and 3TC (Adje-Toure et al., 2003;
Brandin et al., 2003; Descamps et al., 2004; Rodes et al.,
2000; van der Ende et al., 2000, 2003). The significance of
these mutations and their relationship to AZT susceptibility
is not known. Since the natural range of AZT susceptibility
among diverse HIV-2 isolates has not been defined, it is
possible that some of these mutations may be necessary to
enhance AZT resistance in viruses that are naturally less
resistant to AZT. Such a possibility is consistent with in
vitro findings with NNRTIs where evolution of HIV-2
towards higher levels of NNRTI resistance has been
observed despite the inherent baseline resistance of HIV-2
to these drugs (Witvrouw et al., 1999). It is also plausible
that some of these mutations may be important for restoring
lost AZT resistance. This might be the case, for instance, in
HIV-2 mutants containing M184V and Q151M that have
been observed in patients treated with AZT and 3TC (Adje-
Toure et al., 2003; Brandin et al., 2003; Descamps et al.,
2004; Rodes et al., 2000; van der Ende et al., 2000, 2003).
In a similar fashion to HIV-1 (Petrella and Wainberg, 2002),
the M184V mutation might sensitize HIV-2 to AZT and thus
requires the virus to select additional mutations to restore its
resistance to AZT. Experimental evidence to support these
possibilities will be needed.
Our comparative analysis of AZT susceptibility among
HIV-1 and HIV-2 was done in MT-4 cells because of the
demonstrated utility of this cell line in evaluating viral
replication and drug susceptibility (Pauwels et al., 1988;
Vandamme et al., 1999). The direct comparison of several
HIV-1 and HIV-2 isolates was essential for demonstrating
the phenotypic differences between the two viruses.
However, since cell types can influence viral replication
and drug susceptibility testing, we expanded our analysis to
PBMCs and another established T-cell line. We show
further evidence of HIV-2 resistance to AZT by demon-
strating that HIV-2 can also replicate efficiently in PBMCs
and CEM174 cells at high AZT concentrations. Interestingly,
replication of HIV-2 in PBMCs was more efficient than our
control AZT-resistant HIV-1 mutants carrying K70R,
D67N/K70R, or T215Y, suggesting that the levels of AZT
resistance in HIV-2 are higher than those seen in these HIV-
1 mutants.
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two distinct biochemical mechanisms (Scott, 2001). The
first mechanism is frequently seen in mutants carrying
K70R or T215Y and is explained by an increased excision
activity of incorporated AZT by these mutants. A second
mechanism is associated with mutations such as Q151M and
involves an increased ability of the enzyme to discriminate
against AZT-TP (Scott, 2001). Our biochemical data on WT
HIV-1 and HIV-2 RT show that both enzymes have similar
abilities to incorporate AZT, suggesting that the observed
HIV-2 resistance to AZT is not mediated by an increased
discrimination against this drug. Therefore, additional
biochemical studies that evaluate the excision activity of
HIV-2 RT are necessary to determine if this mechanism is
involved in the AZT resistance of HIV-2.
The basis of the observed resistance to AZT in HIV-2 is
not known. However, our sequence comparison between
WT HIV-1 and HIV-2 RT showed important differences
among these two enzymes. The finding of T69N, V75I,
V118I, and K219E in WT HIV-2 RT was of particular
interest since these mutations are all associated with AZT
resistance in HIV-1. For instance, T69N confers about 7-
fold reduction in AZT susceptibility in HIV-1, and V118I,
K219Q, and V75I enhance the levels of AZT resistance of
HIV-1 mutants carrying T215Y/F or Q151M (D’Aquila et
al., 2003; Winters and Merigan, 2001). However, verifying
the possible role of these or other changes in the observed
HIV-2 resistance to AZT will require drug susceptibility
analysis of site-specific mutants.
In summary, our results indicate that the activity of AZT
on HIV-2 is lower than previously thought. The poor
antiviral activity of AZT and the fact that currently approved
NNRTIs are not effective against HIV-2 emphasize the need
for novel antiretroviral drugs specific for HIV-2.Materials and methods
Viruses and drugs
The following viruses were obtained through the AIDS
Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH: HIV-2CDC310319 and HIV-2CDC77618
from Dr. Stefan Wiktor and Dr. Mark Rayfield (Owen et
al., 1998), HIV-2CBL-20/H9 from Dr. Robin Weiss (Schulz et
al., 1990), HIV-1CC/H9, HIV-1IIIB/H9, and HIV-1MN/H9 from
Dr. Robert Gallo (Gallo et al., 1984, 1986; Popovic et al.,
1984a, 1984b; Shaw et al., 1984), and HIV-1LAI from Dr.
Jean-Marie Bechet and Dr. Luc Montaigner (Barre-
Sinoussi et al., 1983; Wain-Hobson et al., 1991). HIV-2
isolate GB122HU was kindly provided by Dr. Ron A.
Otten, and HIV-2 strain ROD was kindly provided by
Dr. Danuta Pieniazek. HIV-2 isolates CDC77618,
CDC310319, and GB122HU are primary isolates from
AIDS patients and have been propagated solely in primary
human PBMCs. HIV-2 CBL-20/H9 and ROD, and HIV-1CC/H9, IIIB/H9, and LAI/PBMC, are laboratory-adapted
strains. HIV-2 CDC77618, ROD, and GB122HU are group
A isolates, and HIV-2 CDC310319 is a group B isolate
(Barre-Sinoussi et al., 1983; Clavel et al., 1986; Gallo et al.,
1986; Owen et al., 1998, 1999; Popovic et al., 1984a,
1984b; Schulz et al., 1990; Wain-Hobson et al., 1991).
HIV-1 HXB2, HXB2S215, and L2S.4Q151M are recombinant
viruses generated by co-transfection of MT-4 cells with an
RT-deleted HXB2-based proviral plasmid and cloned RT
sequences from HXB2 or isolate L2S as previously
described (Garcı´a-Lerma et al., 2000; Hertogs et al.,
1998; Vandamme et al., 1999). The S215 mutation of
HXB2S215 was introduced by site-directed mutagenesis
(Garcı´a-Lerma et al., 2001a). All virus stocks were
aliquoted and maintained at 70 -C. AZT and ddI were
obtained through the NIH AIDS Research and Reference
Reagent Program. AZT-triphosphate (AZT-TP) was
obtained from Moravek Biochemicals (Brea, CA).
Analysis of replication capacity in the presence of AZT
Replication kinetics of HIV-1 and HIV-2 with AZT were
measured in MT-4, CEM174, and human peripheral blood
mononuclear cells (PBMCs). MT-4 and CEM174 cells were
grown and maintained in RPMI 1640 medium comple-
mented with 10% heat-inactivated fetal calf serum, 2 mM l-
glutamine, penicillin/streptomycin, and 0.1% sodium bicar-
bonate. PBMCs were obtained by leukapheresis from an
HIV-1-negative blood donor and were cultured in the same
media containing 10% interleukin-2 (Roche Diagnostics
GmbH, Germany) (Vandamme et al., 1999). Three days
prior to the experiment, PBMCs were enriched for CD4+ T
cells by removing CD8+ T cells with anti-CD8-conjugated
magnetic beads (Dynal, Oslo, Norway) and were activated
in complete media containing 0.5 Ag/ml of phytohemag-
glutinin-P (PHA, Difco, Detroit, MI) as described (Cum-
mins et al., 2003).
Replication kinetics in MT-4 and CEM174 cells were
measured as previously described (Garcı´a-Lerma et al.,
2001a). Briefly, a 500-Al aliquot of HIV-1 or HIV-2
containing 12.5 ng of p24 or p27 antigen was used to
infect 1.5  106 MT-4 or CEM174 cells. After incubation for
2 h at 37 -C, cells were washed with PBS and resuspended
in 10 ml of complete medium containing AZT. Supernatants
from each culture were collected at different days. Levels of
HIV-1 p24 or HIV-2 p27 antigen were quantified in cell-free
supernatants by using the Coulter HIV-1 p24 or SIV p27
antigen assays, respectively, and were used to monitor
replication kinetics. The SIV p27 antigen assay provides a
sensitive method that can be used to monitor kinetics of
HIV-2 replication (Larmoire et al., 1993; Otten et al., 1999).
The lower limit of detection of the HIV-1 p24 and the SIV
p27 antigen assays were 0.0078 ng/ml and 0.05 ng/ml,
respectively. The concentrations of AZT used in experi-
ments done in MT-4 cells were 12.3 Ag/ml for cultures done
with HIV-2 and 1.6 Ag/ml for cultures done with HIV-1. The
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cells was 2 Ag/ml for both HIV-2 and HIV-1.
A similar approach was used to evaluate the kinetics of
virus replication with AZT in PBMCs. Briefly, 1.5  106
activated PBMCs were exposed to each virus stock (12.5 ng
of p24 or p27 antigen) for 2 h at 37 -C. After washing with
PBS, cells were resuspended at 2  106 cells/ml in complete
media containing AZT (2 Ag/ml). 200-Al cultures were done
in quadruplicate using 96-well plates (Costar), and super-
natants (100 Al) were collected at different days followed by
the addition of complete media with AZT. At day 7 of the
experiment, 2  105 PHA-stimulated PBMCs were added to
each culture and cultures were maintained for an additional 7
days.
In vitro selection of drug resistance
Selection of drug resistance was done by sequential
passages of the isolates in the presence of increasing
concentrations of AZT or AZT and ddI as described
previously (Garcı´a-Lerma et al., 2001a). Briefly, a 500-Al
aliquot of HIV-1 or HIV-2 containing 25 ng/ml of p24 or
p27 antigen, respectively, was added to 1.5  106 MT-4
cells and cultured in the presence of AZT (0.024 Ag/ml) or
AZT and ddI (0.003 Ag/ml and 2 Ag/ml, respectively).
Cultures were then incubated at 37 -C and media containing
AZT or AZT and ddI were changed every 3–4 days as
required. Virus production was monitored by microscopic
assessment of syncytium formation. Once virus production
was evident through all the culture, 500 Al of clarified
supernatant was added to 1.5  106 fresh cells and cultured
with the same or a higher concentration of drug/s. The range
of AZT and ddI concentrations used in the selection
experiments is detailed in Tables 1 and 2. Genotypic
changes in the RT were monitored at selected passages by
sequence analysis as described below.
Analysis of the susceptibility to AZT and ddI in HIV-1 and
HIV-2
The susceptibility of HIV-1 and HIV-2 to AZT and ddI
was measured using the MT-4/MTT assay as previously
described (Pauwels et al., 1988; Vandamme et al., 1999).
Briefly, MT-4 cells (3  104) were exposed to 150
CCID50 of each virus in triplicate both in the absence and
in the presence of serial dilutions of AZT or ddI. Control
uninfected MT-4 cell cultures were also included and were
used to correct for drug toxicity. In the standard format of
the assay, the concentration of drug required to inhibit
50% or 90% virus-induced cell killing (50% or 90%
effective concentration; EC50 and EC90, respectively) was
calculated after 5 days in culture by measuring the
reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) by mitochondrial dehydrogenase
of metabolically active cells (Pauwels et al., 1988;
Vandamme et al., 1999).EC50 and EC90 values were also determined using an
extended MT4/MTT assay format that allows for additional
rounds of viral replication in the presence of drug. In this
format, a 40-Al aliquot of each culture was taken at day 5
and transferred to a new 96-well plate containing complete
media with or without drug. EC50 and EC90 values were
then re-calculated after 5 additional days of culture (day 10).
The same procedure was done at day 10 and EC50 and EC90
values were re-calculated at day 14. During the 14 days of
culture, the range of AZT or ddI concentrations remained
constant. Changes in EC50 values >3-fold are considered
significant (cut-off point) (Witvrouw et al., 2004).
Enzymatic susceptibility of HIV-2 RT to AZT-TP
Susceptibility to AZT-TP of virion-associated RTs was
measured using a non-radioactive microtiter plate-based RT
assay (Roche Diagnostics GmbH, Germany) as described
previously (Garcı´a-Lerma et al., 2003). Briefly, viruses
normalized by their levels of RT activity were exposed for
30 min to serial 3-fold dilutions of AZT-TP prepared in lysis
buffer. RT reaction was done for 2 h at 37 -C in an RT buffer
containing poly(A)oligo(dT)15 template/primer, digoxi-
genin-dUTP, biotin-dUTP, and dTTP. Levels of RT activity
were quantified by using an ELISA-based chemilumines-
cent assay according to the manufacturer’s instructions.
Percentage of RT inhibition was determined by dividing the
signal obtained in reactions done with AZT-TP with that
seen in reactions done in the absence of drug; IC50 values
were calculated as previously described (Garcı´a-Lerma et
al., 2003).
RT-PCR and sequence analysis
RT sequences of HIV-1 and HIV-2 were obtained from
amplified RT-nested PCR products using an ABI377
automated sequencer and were analyzed using the Vector
NTI program (Version 7, 2001). Briefly, RNAwas extracted
using the QIAmp Viral RNA kit (Qiagen). For HIV-1, the RT
reaction was done for 1 h at 42 -C using primer RT2 as
described previously (Garcı´a-Lerma et al., 2000). After a first
round of PCR amplification using primers RT1 and RT2, 4 Al
was subjected to a second round of amplification using
primers A35 and NE1. Primers AV36, AV44, A35, and
NE(1)35 were used for sequence analysis (amino acids 32–
224) (Schmit et al., 1996; Vandamme et al., 1999). For HIV-2,
the RT reaction was done for 1 h at 42 -C using primer RT2-2
(5 V -GAA GTC CCA GTC TGG GAT CCATGT CAC TTG
CCA-3 V ). After a first round of PCR amplification using
primers RT2-2 and PR1 (5 V -GGG AAA GAA GCC CCG
CAA CTT C-3 V ), 4 Al was subjected to a second round of
amplification using primers RT7 (5 V -GGG CCA AAG
A(C)TG(C) AGA CAA TGG CC-3 V ) and RT8 (5 V -TTG
GCC AC(G)A GTT CAT AA(G)C CCA TCC-3 V ). Primers
RT7, RT8, RT9 (5 V -CAG TAA ACA ATG CT(A)G AAC
CAG GAA-3 V ), and RT10 (5 V -G T(G)GA TCC CTT CCA
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HIV-2 RT (amino acids 32–224).
Amino acids 225–550 of HIV-2 RT were also sequenced
in baseline isolates and in isolates collected at selected
passages with AZT. Briefly, RNA was extracted using the
QIAmpViral RNA kit and the RT reaction was done for 1 h at
42 -C using primer IN R1 (5 V -TGG GCA CAK GTG TTT
ACT ATC TG-3 V ). After a first round of PCR amplification
using primers INR1 and RT11 (5 V -ATCYTAATRGCTAGT
GAC AGG A-3 V ), 5 Al was subjected to a second round of
amplification using primers RT12 (5 V -GAGAAG TTC CAA
AAR GAC CTC C-3 V ) and RT13 (5 V -TGT CTR ATG CCY
TGACTTACTA-3 V ). Primers RT12, RT13, RT14 (5 V -AAG
TCC CAW TCT GGG ATC CAT G-3 V ), and RT15 (5 V -ACC
TGG GAR CAG TGG TGG GAT A-3 V ) were used for
sequence analysis. Nucleotide RT sequences (amino acids
32–550) of baselineHIV-2 isolates CDC77618, CDC310319,
GB122HU, ROD, and CBL20/H9 and of isolates collected at
passage 10 with AZT have been deposited in the GenBank
database (accession numbers AY965902–AY965911).Acknowledgments
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